atc2022

COMMITTEE

The agenda is being shaped by industrial key opinion leaders and scientists, with members including:

Program Committee

Chung-Hsiun Wu 吳忠勳

President, DCB

More

Chung-Hsiun Wu 吳忠勳

President, DCB

Education

▌Ph.D. in Biochemistry, University of Maryland, U.S.A.

▌B.Sc. in Botanics, National Taiwan University, Taiwan

Experience

▌2018~ present, President, Development Center for Biotechnology (DCB)

▌Director, Biotechnology and Pharmaceutical Industries Promotion Office, MOEA

▌Chairman, Taiwan Bio Industry Organization

▌Chairman, Taiwan Antibody Association

▌Vice President, Precision Medicine & Molecular Diagnostics Industry Association of Taiwan

▌Director, Institute for Biotechnology and Medicine Industry(IBMI)

▌Director, Taipei Biotechnology Service and Business Trade Association

▌Director, Chinese Association for Industrial Technology Advancement

▌Director, Taiwan Pharmaceutical Manufacture and Development Association

▌Supervisor, Monte Jade Science and Technology Association of Taiwan

▌2017~ 2018, Acting President, Development Center for Biotechnology (DCB)

▌2017~ 2018, Vice President, Development Center for Biotechnology (DCB)

▌2014~2017, Executive Director, Institute of Biologics, Development Center for Biotechnology (DCB)

▌2013~2014, Director/Senior Research Fellow, Department of Protein Engineering, Development Center for Biotechnology (DCB)

▌2008~2009, Founder/Chairman/CEO, Geniusway Biotech.

▌2006~2008, Founder/Chairman/CEO, Geniusway Technology

▌2000~2004, Cofounder/Chief Scientific Officer/Vice President of Business Development, AbGenomics Inc.

▌1996~2000, Associate Professor, Institute of Molecular Medicine, College of Medicine, National Taiwan University

▌1995~1996, Lecturer, Institute of Molecular Medicine, College of Medicine, National Taiwan University

▌1992~1995, Jane-Coffin-Childs Memorial Fund Fellow, Department of Embryology, Carnegie Institution of Washington, Baltimore, Maryland, USA
Han-Chung Wu 吳漢忠

Director, BioTReC

More

Han-Chung Wu 吳漢忠

Director, BioTReC

Director of the Biomedical Translation Research Center (BioTReC), Academia Sinica,

Distinguished Research Fellow of the Institute of Cellular and Organismic Biology, Academia Sinica

Fellow of the National Academy of Inventors (NAI)

Dr. Han-Chung Wu is currently a Distinguished Research Fellow of the Institute of Cellular and Organismic Biology, Academia Sinica, Taiwan. He is also a Professor at the College of Medicine of the National Taiwan University. His research primarily focuses on two fields, cancer research and infectious diseases, and includes components of both basic research and applied science. Dr. Wu's research interest focuses on the identification of novel tumor antigens, development of targeting drug delivery systems for cancer therapy and molecular imaging. He has developed phage display technologies for the generation of fully human monoclonal antibodies and the identification of peptides for a variety of target molecules. As of today, Dr. Wu has published over 128 original articles in world-renowned journals, and 122Patents (including 84 granted patents and 38 filed patents). He has successfully licensed out 20 technologies from 68 patents to biotech companies. Seven of the licensed technologies serve as the basis for products that are currently in clinical trials or already on the market. Seven of the licensed technologies are currently in preclinical studies for the development of therapeutics. Hence, his research results not only have significant value in basic research, but also practical applications with tangible contributions to the development of the biotech industry and drug development. Dr. Wu was elected as a Fellow of the National Academy of Inventors (NAI) of the United States in 2020. This is among the highest achievable honors for an academic inventor.

Aside from conducting research, Dr. Wu has also been responsible for coordinating academic activities and overseeing administration at the Institute of Cellular and Organismic Biology as the Vice Director and Acting Director. He had also served as the Director of the Department of Intellectual Property and Technology Transfer, Academia Sinica, to promote the protection of intellectual property and the technology transfer, and use the industrialization of intellectual property rights to enhance social welfare. In 2019, Dr. Wu joined National Research Biotechnology Park (NBRP), Academia Sinica, as Chief Executive Officer of BioHub Taiwan. He is currently serving as the Director of Biomedical Translation Research Center, NBRP, Academia Sinica, with the mission of promoting the biotechnology industry development in Taiwan.

Professional Experience

•Director, Biomedical Translation Research Center, Academia Sinica, Taiwan

•Distinguished Research Fellow, Institute of Cellular and Organismic Biology, Academia Sinica

•Chief Executive Officer, National Biotechnology Research Park/BioHub Taiwan

•Director, Department of Intellectual Property and Technology Transfer, Academia Sinica

•Acting Director, Institute of Cellular and Organismic Biology, Academia Sinica

•Vice Director, Institute of Cellular and Organismic Biology, Academia Sinica

•Research Fellow, Institute of Cellular and Organismic Biology, Academia Sinica

•Joint Appointment Professor, Institute of Pathology; and Graduate Institute of Oral Biology, College of Medicine, National Taiwan University
Tse-Wen Chang 張子文

President,

Immunwork, Inc.

More

Tse-Wen Chang 張子文

President,

Immunwork, Inc.

EDUCATION AND POSITIONS HELD:

•B.S. & M.S., Chemistry, National Tsing Hua University, Taiwan, 1966-1972

•Ph.D., Cell and Developmental Biology, Harvard University, 1973-1977

•Postdoctoral Fellow, Center for Cancer Research, M. I. T., 1977-1980

•Supervisor of Cellular Immunology, Ortho Pharmaceutical Corp., 1980-1981

•Director of Immunology, V. P. of Research, Centocor, Inc., 1981-1985

•Professor of Molecular Virology, Baylor College of Medicine, 1986-1991

•Cofounder 1986, and V.P. of R & D, 1986-1996, Tanox, Inc., Houston

•Professor 1996-2003; Dean 1996-1999; Tsing Hua Professor of Life Science 2003-2006; College of Life Science, National Tsing Hua University

•President, Development Center for Biotechnology, Taipei, 2000-2003

•Distinguished Professor, Genomics Research Center, Academia Sinica, 2006-2015

•Distinguished Visiting Chair, Genomics Research Center, Academia Sinica, 2016-present

RESEARCH INTERESTS:

•New drug discovery and antibody engineering

•The main focus of our group is to develop humanized antibody-based and immunogen-based therapeutics, which target key molecules involved in IgE-mediated allergic pathway. We are also developing new technology platforms for improved antibody engineering. One such program is to develop humanized antibody against CεmX domain in human membrane-bound IgE, for the purpose of controlling IgE-expressing B lymphocytes. CεmX, discovered by our group, is a 52 a.a. domain with a unique sequence. Anti-CεmX, if successfully developed, may be used in combination with an anti-IgE antibody, such as omalizumab (trade name Xolair), which is also derived from Dr. Chang's invention and which is approved for allergic asthma.
Karen Wen 溫國蘭

COO, GenomeFrontier

More

Karen Wen 溫國蘭

COO, GenomeFrontier

2019.3 - present

Chief Strategy Officer (CSO)Chief Strategy Officer (CSO), GenomeFrontier

therapeutics,Inc.

Experience

2011-2018 President of Mycenax Biotech Inc.

2001-2011 Vice President and Manager, Department of Quality Assurance of Mycenax Biotech Inc.

Co-founder of Mycenx Biotech Inc. Specialized in drug development, biological development,PIC/S GMP and GDP, IVD development, ISO system, monoclonal antibody development, and business development.

1993-2000

Principal Researcher, Development Center for Biotechnology

Research Fellow of Development Center for Biotechnology, and head of research and development of ISO plant for IVD

Education

Old Dominion University/ Eastern Virginia Medical School

Doctor of Philosophy – PhD, Biomedical Science

National Taiwan University

Bachelor of Science – BS, Chemistry

Sponsor Committee

Wei-Kuang Chi, Ph.D. 紀威光

Consultant, Executive Director, Institute of Pharmaceutics,

Development Center for Biotechnology

生物技術開發中心特約專家

More

Wei-Kuang Chi, Ph.D. 紀威光

Consultant, Executive Director, Institute of Pharmaceutics,

Development Center for Biotechnology

生物技術開發中心特約專家
Chih-Jung Chang, Ph.D. 張志榮

Secretary General, Taiwan Antibody Association (TAA)

COO, EirGenix Inc.

台灣抗體協會秘書長/台康生技股份有限公司營運長

More

Chih-Jung Chang, Ph.D. 張志榮

Secretary General, Taiwan Antibody Association (TAA)

COO, EirGenix Inc.

台灣抗體協會秘書長/台康生技股份有限公司營運長

Vice President, Chief Operating Officer (COO)

Dr Chih-Jung Chang is an Organic Chemist and has majored on the pharmaceutical field for nearly 20 years. He once worked as the director of TOT Oncology Business Unit at TTY Biopharm. During which, his main responsibilities included project management creating business and drug development strategies for licensing and collaboration in global NCE (Specialty)/Biologics (NBE/Biosimilars) projects.

With both technical knowledge and business acumen, Dr. Chang has extensive experiences building up new biologics and specialty pipelines that fit the company’s development strategy. In addition, Dr Chang has extensive experiences managing international networking and relationships for value-added bridge between early and late stage drug development. In particular, Dr Chang has extensive experiences working with global CRO/CMO resources to fast track drug development.

Before assuming the current position, Dr Chang was with TaiGen Biotechnology and was in charge of managing the company’s R&D projects and business development.

Organizers

Supporting Organizers

Sponsors

Media